82F.F NFL BIOSCIENCES EO -03
- Market cap
- EUR 3.96M
- P/E
- -
- P/B
- 20.16x
- ROE
- -1,083.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 82F.F undervalued?
Graham numberThe Graham number of NFL BIOSCIENCES EO -03 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NFL BIOSCIENCES EO -03 fundamental analysis
No fundamental analysis for NFL BIOSCIENCES EO -03 yet.
NFL BIOSCIENCES EO -03 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NFL BIOSCIENCES EO -03
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NF…
Full company profileNFL BIOSCIENCES EO -03 financial statements
NFL BIOSCIENCES EO -03 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -531K | -2.24M | -3.48M | -1.55M | -2.52M |
| Operating Income | -1.12M | -3.09M | -4.23M | -2.79M | -3.87M |
| EBITDA | - | -2.80M | -4.05M | -2.65M | -3.76M |
| Net Income | -978K | -2.44M | -3.75M | -2.08M | -3.32M |
| EPS | -0.19 | -0.47 | -0.46 | -0.21 | -0.26 |
| Balance Sheet | |||||
| Total Assets | 3.69M | 2.40M | 3.97M | 3.61M | 3.66M |
| Total Liabilities | 398K | 1.55M | 3.62M | 2.63M | 3.36M |
| Shareholders' Equity | 3.29M | 844K | 350K | 976K | 306K |
| Cash & Short-term Investments | 3.04M | 1.05M | 2.34M | 1.91M | 2.00M |
| Cash Flow | |||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | |||||
| ROE | -29.8% | -289.5% | -1,070.3% | -213.1% | -1,083.8% |
| ROA | -26.5% | -102.0% | -94.3% | -57.6% | -90.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
NFL BIOSCIENCES EO -03 dividends
NFL BIOSCIENCES EO -03 has not paid dividends in the last 5 fiscal years.
Who owns NFL BIOSCIENCES EO -03
- Insiders 14.21%
- Institutions 0.00%
- Public & others 85.79%
- Shares outstanding 12.7M
- Free float 10.9M
NFL BIOSCIENCES EO -03 company profile
- Company name
- NFL BIOSCIENCES EO -03
- Ticker
- 82F.F
- ISIN
- FR0014003XT0
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 199 Rue HElEne Boucher, Castelnau-le-Lez, France, 34170
- Phone
- 33 4 11 93 76 67
- Website
- nflbiosciences.com
About NFL BIOSCIENCES EO -03
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.
NFL BIOSCIENCES EO -03 management
5- Mr. Bruno Lafont M.B.A., M.Sc.Founder, CEO, MD & Chairman
- Mr. Guillaume AudemaChief Financial Officer
- Dr. Ignacio Faus M.B.A., Ph.D.Deputy MD & Director
- Dr. Yannick Pletan M.D., M.Sc.Chief Medical Officer & Director · born 1953
- Ms. Lara Babich Ph.D.Head of Development & Manufacturing